Baker Bros. Advisors LP Halozyme Therapeutics, Inc. Transaction History

Baker Bros. Advisors LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$14.93 - $19.53 $4.48 Million - $5.86 Million	-299,969 Closed	0 $0
Q4 2018 Feb 13, 2019	SELL	$13.33 - $18.66 $2 Million - $2.8 Million	-150,000 Reduced 33.34%	299,969 $4.39 Million
Q3 2018 Nov 14, 2018	SELL	$16.68 - $18.41 $13.9 Million - $15.4 Million	-833,960 Reduced 64.95%	449,969 $8.18 Million
Q2 2018 Aug 14, 2018	SELL	$16.87 - $20.3 $5.02 Million - $6.04 Million	-297,495 Reduced 18.81%	1,283,929 $21.7 Million
Q3 2017 Nov 14, 2017	BUY	$11.76 - $17.4 $18.6 Million - $27.5 Million	1,581,424	1,581,424 $27.5 Million

542

125M

294K

180K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $7.35B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.